Zobrazeno 1 - 10 of 26 pro vyhledávání: '"Börje Darpö"'
1
Akademický článek
Diurnal QT analysis in patients with sotalol after cardioversion of atrial fibrillation
Autor: Hanna Lenhoff, Börje Darpö, Alex Page, Jean Philippe Couderc, Per Tornvall, Mats Frick
Publikováno v: Annals of Noninvasive Electrocardiology, Vol 26, Iss 4, Pp n/a-n/a (2021)
Abstract Background The risk of ventricular arrhythmias in patients on QT prolonging drugs is indicated to be increased early after cardioversion (CV) of atrial fibrillation (AF) to sinus rhythm (SR). Sotalol, used to prevent AF relapse, prolongs car
Externí odkaz: https://doaj.org/article/eff5e8a9be0d4e52aa3b0ccf7aa369be
Zobrazit plný text záznamu
2
[Untitled]
Autor: Hans Vallin, Börje Darpö, Harry Jgm Crijns, Per Blomström, Birgitta Houltz, Johannes Brachmann, Elisabeth Svernhage, Steen M Jensen, Karl Swedberg, Nils Edvardsson
Publikováno v: Cardiovascular Drugs and Therapy. 13:329-338
Purpose: To assess the efficacy of the I-kr-blocker almokalant attempting to convert chronic atrial tachyarrhythmias, and to find predictors of conversion, to sinus rhythm. Methods: The electrophysiological effects of a 6-hour infusion of almokalant,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66825095d83b2f5b750bd21c8ce7def2
https://doi.org/10.1023/a:1007759500274
Zobrazit plný text záznamu
3
Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study
Autor: Steen M. Jensen, Hans Vallin, Johannes Brachmann, Harry J.G.M. Crijns, Elisabeth Svernhage, Birgitta Houltz, Per Blomström, Karl Swedberg, Börje Darpö, Nils Edvardsson
Publikováno v: Pace-Pacing and Clinical Electrophysiology, 21(5), 1044-1057. Wiley
The aim of this study was to identify predictors of torsades de pointes (TdP) in patients with atrial fibrillation (AF) or flutter exposed to the Class III antiarrhythmic drug almokalant. TdP can be caused by drugs that prolong myocardial repolarizat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b96f3d9f1b3b4c06586ed84051be68
https://doi.org/10.1111/j.1540-8159.1998.tb00150.x
Zobrazit plný text záznamu
4
[Untitled]
Autor: Börje Darpö, Nils Edvardsson
Publikováno v: Cardiovascular Drugs and Therapy. 11:499-508
The aim of the present study was to investigate the effects of almokalant on sustained reentrant supraventricular tachycardias. Reentrant tachycardias were induced, using transesophageal atrial stimulation, in 82 patients with atrioventricular reentr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b6f139138d8aac290009df188b7d867
https://doi.org/10.1023/a:1007761825414
Zobrazit plný text záznamu
5
Assessment of frequency dependency of the class III effects of almokalant: A study using programmed stimulation and recording of monophasic action potentials and ventricular paced QT intervals
Autor: Olle Almgren, Robert Bergstrand, Stefan Franzén, Nils Edvardsson, Börje Darpö
Publikováno v: Cardiovascular Drugs and Therapy. 10:539-547
The aim of the present study was to assess the frequency dependency of the effects of almokalant, a selective class III antiarrhythmic drug, on ventricular repolarization using recordings of monophasic action potentials and measurements of ventricula
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::397ede397e5fdc199a03bfbadedf36ac
https://doi.org/10.1007/bf00050994
Zobrazit plný text záznamu
7
Selective Ik Blocker Almokalant Exhibits Class Ill-Specific Effects on the Repolarization and Refractoriness of the Human Heart
Autor: Olle Almgren, Hans Vallin, Nils Edvardsson, Börje Darpö, Per Insulander, Robert Bergstrand
Publikováno v: Journal of Cardiovascular Pharmacology. 26:530-540
Almokalant, a recently developed potassium-channel blocker, has exhibited properties of a selective class III agent in vitro and in animal experiments. We report the first invasive study in humans in which the electrophysiological characteristics of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a9dbed73372c4cb0ed344e11d13dd354
https://doi.org/10.1097/00005344-199510000-00005
Zobrazit plný text záznamu
8
Effect of Almokalant, a Selective Potassium Channel Blocker, on the Termination and Inducibility of Paroxysmal Supraventricular Tachycardias
Autor: Nils Edvardsson, Börje Darpö
Publikováno v: Journal of Cardiovascular Pharmacology. 26:198-206
Almokalant is a newly developed selective blocker of the delayed outward K+ current and exhibits the electrophysiological properties of a class III antiarrhythmic agent. In a Scandinavian multicenter, placebo-controlled trial, the antiarrhythmic effi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e167cb598887bb5cbfba5d50a24fab93
https://doi.org/10.1097/00005344-199508000-00004
Zobrazit plný text záznamu
9
Tolerance and Effects of Almokalant, a New Selective Ik Blocking Agent, on Ventricular Repolarization and on Sino-Atrial and Atrioventricular Nodal Function in the Heart
Autor: Robert Bergstrand, Börje Darpö, Nils Edvardsson, Christer Gottfridsson, Olle Almgren, Bengt Sandstedt, Catharina Bäärnhielm
Publikováno v: Journal of Cardiovascular Pharmacology. 25:681-690
Almokalant, (4-(3-ethyl(3-propylsulfinyl)propyl)amino)-2-hydroxy-propoxy)- benzonitrile), is a newly developed Ik channel blocker that exhibits pure class III effects. Using a noninvasive approach with transesophageal atrial stimulation (TAS), we wis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8554236145bb405e978b0b1f60e2154
https://doi.org/10.1097/00005344-199505000-00001
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje